Treatment Algorithm for Relapsed/Refractory DLBCL

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.

Azer-cel elicited strong and durable responses in patients with heavily pretreated relapsed/refractory DLBCL in a phase 1b trial.